Company: IXHL
Filing Date: 2025-10-27
Form Type: DEF 14A
Source: 0001213900-25-102654
Chunk: 12

Company: Incannex Healthcare Inc.
Filing Date: 2025-10-27
Form: DEF 14A
Chunk 12
---
 three years to serve until the 2028 annual meeting of stockholders, and until their respective successors have been elected and qualified, subject to their earlier death, resignation or removal. Set forth below are the names of the persons nominated for election as directors and those directors whose terms do not expire this year, their ages, their offices in the Company, if any, their principal occupations or employment for at least the past five years, the length of their tenure as directors and the names of other public companies in which such persons hold or have held directorships during the past five years as of October 10, 2025. Additionally, information about the specific experience, qualifications, attributes or skills that led to our board of directors’ conclusion at the time of filing of this proxy statement that each person listed below should serve as a director is set forth below:

| Name                  |     | Age |     | Position with the Company                       |
| Joel Latham           |     |  36 |     | Chief Executive Officer, President and Director |
| Troy Valentine        |     |  52 |     | Chairperson                                     |
| Peter Widdows         |     |  59 |     | Director                                        |
| Dr. George Anastassov |     |  61 |     | Director                                        |
| Robert Clark          |     |  65 |     | Director                                        |

Joel Latham.Joel Latham has served as Chief Executive Officer, President, and Director of the Company since July 2023. Mr. Latham brings over 20 years of experience across public and private sectors, including nine years with the Incannex group and seven years as its Chief Executive Officer. Under his leadership, Incannex has evolved from an emerging Australian biotech into a Nasdaq-listed clinical-stage pharmaceutical company pioneering innovative combination therapies. Prior to the Company’s re-domiciliation to the United States in November 2023, Mr. Latham served as Chief Executive Officer and Managing Director of Incannex Healthcare Limited (now a subsidiary of the Company), where he was instrumental in driving strategic growth, advancing multiple clinical assets, and successfully overseeing the transition to the Nasdaq Stock Market. Since joining Incannex in 2016 as General Manager, Mr. Latham has led initiatives that strengthened the Company’s R&D pipeline, expanded its global footprint, and enhanced shareholder value. Earlier in his career, he held senior roles with Mars Foods, Tabcorp, and Philip Morris International, gaining deep expertise in corporate strategy, operations